RICHMOND TIMOTHY J.

EVP Chief HR Officer Richmond sells 21,250 shares in 3 transactions for $4.5M at $210.45 avg; holdings drop to 6,130 shares

Timothy J. Richmond, EVP and Chief HR Officer, executed 3 separate sales totaling 21,250 shares for $4,472,038.78 at a blended average price of $210.45 on 2025-03-03. This represents a substantial reduction of his ABBV holdings from 27,380 shares to 6,130 shares, a -77.6% decrease in position size. The stock is trading at $207.76 currently, down -1.8% from its 52-week high of $211.48, and has appreciated +13.0% over the past 30 days and +17.7% over the past 90 days. Richmond's cross-ticker track record shows 10 prior sells with a 100.00% well-timed rate at the 90-day mark, though at ABBV specifically, his 5 prior transactions on 2025-02-26 remain outcome-not-yet-measurable; this large sale follows closely on those recent sales just one week prior.

EVP Chief HR Officer Richmond sells 29,917 shares ($6.1M) at $202.90 avg; retains 44.3K shares post-transaction

Timothy J. Richmond, EVP and Chief HR Officer at AbbVie, executed six separate sales on 2025-02-26 totaling 29,917 shares for $6,070,036.16 at a blended average price of $202.90, reducing his holdings by -40.3% from 74,201 to 44,284 shares. The magnitude of this sale—nearly $6.1M in aggregate—represents a substantial reduction in his equity position. Notably, Richmond's cross-ticker track record shows a 100% well-timed rate on prior sells (4 prior sales with avg 90d return -11.7%), and his prior trades at ABBV itself display consistent patterns: all 4 prior sales (dating 2024-03-01) were well-timed at the 90-day mark, posting negative 90-day returns ranging from -11.4% to -12.0%. The current stock price of $209.03 sits at the 52-week high (+0.0% from peak), and the 30-day and 90-day momentum has been positive (+19.3% and +14.3% respectively), creating a backdrop where this large liquidation contrasts with recent strength. The combination of his substantial position reduction, his demonstrated pattern of well-timed selling at this ticker, and the current valuation context warrants investor scrutiny into potential forward signaling.